East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg. Aurobindo Pharma’s Bupropion Hydrochloride Extended-Release Tablets USP (XL), are an AB-rated generic equivalent to the reference listed drug (RLD), Wellbutrin XL® […] The post Aurobindo Receives FDA Approval for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 150 mg and 300 mg appeared first on Aurobindo Pharma USA .